Efficacy of the iron-chelating agent, deferiprone, in patients with Parkinson's disease: A systematic review and meta-analysis.

Ahmed NegidaNafisa M HassanHeba AboeldahabYoumna E ZainYasmin NegidaShirin CadriNivin CadriLeslie J CloudMatthew J BarrettBrian Berman

Published in: CNS neuroscience & therapeutics (2024)

Current evidence does not support the use of DFP in PD patients. Future disease-modification trials with better population selection, adjustment for concomitant medications, and long-term follow up are recommended.

Keyphrases

end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
patient reported outcomes
current status
iron deficiency